March 30, 2025 - 09:12

In the coming week, the financial landscape is poised for significant developments as former President Donald Trump prepares to unveil his highly anticipated tariff announcements. These measures could have far-reaching implications for various sectors of the economy, especially as businesses and investors brace for potential shifts in trade dynamics.
Simultaneously, a crucial labor market report is scheduled for release, which analysts believe will provide critical insights into the health of the economy. With unemployment rates and job growth figures in the spotlight, this report could greatly influence investor sentiment and market stability.
As the stock market faces a downturn, the combination of Trump’s tariff decisions and the labor report may create a volatile environment. Market participants are closely monitoring these events, as they could dictate trading strategies and economic forecasts in the near term. Investors are urged to stay informed as these developments unfold, potentially reshaping the economic outlook.
May 14, 2026 - 00:55
Aeluma Announces Third Quarter Fiscal 2026 Financial ResultsAeluma, Inc., a company specializing in compound semiconductor technologies, has released its financial results for the third quarter of fiscal year 2026. The report comes alongside several major...
May 13, 2026 - 11:31
MCK Q1 Deep Dive: Revenue Misses Analyst Expectations as Margin Initiatives ContinueHealthcare distributor McKesson reported first-quarter earnings that missed revenue expectations, though the company continued to push ahead with margin-focused initiatives. For the quarter ending...
May 12, 2026 - 23:07
Prudential Financial Declares Quarterly Dividend on Common StockNEWARK, N.J., May 12, 2026 -- Prudential Financial, Inc. has declared a quarterly dividend of $1.40 per share on its common stock. The payment is scheduled for June 11, 2026, and will go to...
May 12, 2026 - 03:06
Cellectis Reports First Quarter 2026 Financial ResultsCellectis has announced its financial results for the first quarter of 2026, alongside updates on its clinical pipeline and preclinical research programs. The company is advancing its pivotal...